Myocardial toxicity in a group of greyhounds administered ractopamine
| Autor: | Steve Ensley, R. E. Slavin, Wendy A. Ware, Michael J. Yaeger, K. Mullin |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Agonist
medicine.medical_specialty Necrosis medicine.drug_class Administration Oral Performance-Enhancing Substances Muscle hypertrophy chemistry.chemical_compound Dogs Oral administration Internal medicine Phenethylamines medicine Animals Dog Diseases Muscle Skeletal General Veterinary biology business.industry Myocardium Skeletal muscle Arrhythmias Cardiac Adrenergic beta-Agonists Troponin Ractopamine Substance Abuse Detection Endocrinology medicine.anatomical_structure chemistry Toxicity biology.protein medicine.symptom business |
| Zdroj: | Veterinary pathology. 49(3) |
| ISSN: | 1544-2217 |
| Popis: | Ractopamine, a synthetic β2-adrenoceptor agonist, is widely used as a feed additive in the United States to promote a reduction in body fat and enhance muscle growth in cattle, pigs, and turkeys. It has the potential for illegal use in show and racing animals because it may affect performance via its β-adrenergic agonist properties or anabolic activities. Nine greyhounds were orally administered 1 mg/kg of ractopamine to investigate the ability to detect the drug in urine. Postdosing, 7 of 9 dogs developed cardiac arrhythmias and had elevated troponin levels indicating myocardial damage. One dog necropsied 4 days postdosing had massive myocardial necrosis, mild to focally moderate skeletal muscle necrosis, and widespread segmental arterial mediolysis. A second dog necropsied 17 days postdosing had mild myocardial necrosis and fibrosis. Scattered arteries exhibited segmental medial and perimedial fibromuscular dysplasia. This is the first reported case of arterial, cardiac, and skeletal muscle damage associated with ractopamine. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|